<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738020</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL008</org_study_id>
    <nct_id>NCT03738020</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Correction of Wrinkles and Folds and Safety of YVOIRE Classic Versus Restylane in Nasolabial Fold Intradermal Injection</brief_title>
  <official_title>A Randomized, Multi Center, Single-blind, Active-controlled, Matched Pairs Design Clinical Study to Evaluate the Correction of Wrinkles and Folds and Safety of HA IDF Versus Restylane in Nasolabial Fold Intradermal Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was purposed to evaluate the non-inferiority of HA IDF, a hyaluronic acid product,
      in terms of correction of wrinkles and safety in nasolabial fold intradermal injection,
      compared to Restylane, the control preparation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>IND approved from KFDA</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average of Wrinkle Severity Rating Scale (WSRS) Score Evaluated by the Evaluating Investigator at Week 26 (Visit 7) After the Final Treatment With the Investigational Medical Device</measure>
    <time_frame>Week 26 (Visit 7)</time_frame>
    <description>Wrinkle Severity Rating Scale (WSRS)
Absent: no visible fold; continuous line
Mild: Shallow but visible fold with slight indentation; minor facial feature
Moderate: moderately deep fold; clear facial feature visible at normal appearance but not when stretched. Excellent correction expected.
Severe: very long and deep; prominent facial feature; less than 2mm visible fold when stretched
Extreme: extremely deep and long folds; 2-4mm visible v-shaped fold when stretched; detrimental to appearance; unlikely to have satisfactory correction with injectable implant alone</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Temporary Correction of Wrinkles</condition>
  <arm_group>
    <arm_group_label>HA IDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HA IDF (YVOIRE classic)</intervention_name>
    <description>Treatment with HA IDF</description>
    <arm_group_label>HA IDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane</intervention_name>
    <description>Treatment with Restylane</description>
    <arm_group_label>Restylane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: Women in 30~55 years.

          2. Those whose wrinkle scores in the treatment site (nasolabial fold) at the screening
             visit were Stage 3 or 4 in the 5-stage Wrinkle Severity Rating Scale (WSRS)
             symmetrically and who were informed on this study in detail, understood it completely,
             decided to participate in the study own their own and signed on the informed consent.

        Exclusion Criteria:

          1. Those with a skin disease in the face (skin infection, eczema, psoriasis, rosacea,
             herpes etc.) or those with a history of severe allergy.

          2. Patients with a disorder in autoimmune system

          3. Those with hepatic dysfunction or abnormality in coagulation, or those administering
             an anticoagulant (aspirin, warfarin etc.) concomitantly

          4. Those who had used a local topical preparation (steroid, retinoid) within 4 weeks
             prior to the study.

          5. Those who had underwent a chemical peeling, laser procedure (including IPL) or
             insertion of other bioadaptive material within 3 months prior to the study (however,
             those who had been treated with HA filler could participate in the study if the date
             of treatment was known and the investigator judged that the filler effect had
             disappeared).

          6. Patients with a malignant tumor

          7. Women in pregnancy or lactation

          8. Hepatitis carriers or VDRL/HIV positive patients

          9. Those with a hypersensitivity to the investigational medical device of this study

         10. Other persons including those considered as difficult to perform this study by the
             principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <results_first_submitted>November 27, 2018</results_first_submitted>
  <results_first_submitted_qc>November 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>spilt-face design</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects</title>
          <description>Subjects who enrolled in this study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>spilt-face design</population>
      <group_list>
        <group group_id="B1">
          <title>HA IDF and Restylane</title>
          <description>Subjects who were included in efficacy evaluation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.40" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average of Wrinkle Severity Rating Scale (WSRS) Score Evaluated by the Evaluating Investigator at Week 26 (Visit 7) After the Final Treatment With the Investigational Medical Device</title>
        <description>Wrinkle Severity Rating Scale (WSRS)
Absent: no visible fold; continuous line
Mild: Shallow but visible fold with slight indentation; minor facial feature
Moderate: moderately deep fold; clear facial feature visible at normal appearance but not when stretched. Excellent correction expected.
Severe: very long and deep; prominent facial feature; less than 2mm visible fold when stretched
Extreme: extremely deep and long folds; 2-4mm visible v-shaped fold when stretched; detrimental to appearance; unlikely to have satisfactory correction with injectable implant alone</description>
        <time_frame>Week 26 (Visit 7)</time_frame>
        <population>Spilt-face design</population>
        <group_list>
          <group group_id="O1">
            <title>HA IDF</title>
            <description>HA IDF (YVOIRE classic): Treatment with HA IDF</description>
          </group>
          <group group_id="O2">
            <title>Restylane</title>
            <description>Restylane: Treatment with Restylane</description>
          </group>
        </group_list>
        <measure>
          <title>Average of Wrinkle Severity Rating Scale (WSRS) Score Evaluated by the Evaluating Investigator at Week 26 (Visit 7) After the Final Treatment With the Investigational Medical Device</title>
          <description>Wrinkle Severity Rating Scale (WSRS)
Absent: no visible fold; continuous line
Mild: Shallow but visible fold with slight indentation; minor facial feature
Moderate: moderately deep fold; clear facial feature visible at normal appearance but not when stretched. Excellent correction expected.
Severe: very long and deep; prominent facial feature; less than 2mm visible fold when stretched
Extreme: extremely deep and long folds; 2-4mm visible v-shaped fold when stretched; detrimental to appearance; unlikely to have satisfactory correction with injectable implant alone</description>
          <population>Spilt-face design</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="0.68"/>
                    <measurement group_id="O2" value="2.56" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HA IDF</title>
          <description>Subject who were injected with investigational medical device at least once</description>
        </group>
        <group group_id="E2">
          <title>Restylane</title>
          <description>Subject who were injected with investigational medical device at least once</description>
        </group>
        <group group_id="E3">
          <title>Systemic</title>
          <description>Subject who were injected with investigational medical device at least once</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Leader</name_or_title>
      <organization>LG Chem</organization>
      <phone>82-2-6987-4148</phone>
      <email>sodam@lgchem.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

